Clinical Trial

The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children

Study acronym: LEVET
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 12, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06498362
Lead Sponsor University Hospital, Strasbourg, France
Conditions Epilepsy in Children
Enrollment 151 participants
Start Date 2023-11-16
Primary Completion 2025-05 (estimated)
Study Completion 2025-05-16 (estimated)
Updated on ClinicalTrials.gov 2024-07-12